Based on my assumptions of approx 38-40 dispensaries by EOY (assuming no mergers) and revs of $185MM (conservatively employing something in the lower range of earnings guidance) of with 138MM fully diluted shares, a market cap should approach $393MM with a pps of $2.85 EBITDA in range of $0.05 -0.10 or 28 Adjusted PE.
As for your second question With said sacred herb off Sched 1 and potential up listing (off from OTC) will be significantly higher. Approaching highest single digits at least. Because...
Intangibles...debt service and financing opportunities with up listing are significant potential positives. This bias would lift the entire sector and I cannot see Schwazze not being acquired or built out with it for a premium ($25-30) within a few years. But I'm a simple Ihub board member with a dirty crystal ball. This conference call helped clarify some things as it was far cleaner than the last 10Q. We get what we pay for. Strong team, strong results. The nature of the derivatives do remain a paper gotcha that has to be factored. Any recovery in share price tips the balance sheet downward. Well, that sucks on paper. I'd rather have a crappy looking paper loss and a vibrant stock with continued expansion though. Balance? I think our guys 'n gals will get ahead of that this this year.
News 
Market Data 
Discover 
AI
